Ensysce Biosciences Soars 24.64% on Patent Win, NDA Plans

On May 14, 2025, Ensysce Biosciences experienced a significant surge in its stock price, rising by 24.64% in pre-market trading.

Ensysce Biosciences recently reported its first-quarter 2025 financial results, which included a net loss of $1,945,573. The company also received a U.S. patent for a groundbreaking treatment for opioid use disorder, which has been a significant development for the company.

In addition to its financial performance, Ensysce Biosciences has been actively bolstering its management team. The company plans to submit its New Drug Application (NDA) for PF614 in 2026, following the completion of its Phase 3 pivotal study. This strategic move is expected to further enhance the company's position in the market.